Denosumab for treatment of bone metastases secondary to solid tumours: Systematic review and network meta-analysis
| Autor: | Andrew Elders, Pawana Sharma, C Mulatero, John Ford, Radha Todd, Robert Jones, Fiona Stewart, Pamela Royle, Graham Mowatt |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Antineoplastic Agents Bone Neoplasms Cochrane Library Antibodies Monoclonal Humanized Placebo Prostate cancer Breast cancer Quality of life Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans business.industry medicine.disease Survival Analysis Surgery Denosumab Zoledronic acid Meta-analysis business medicine.drug |
| Zdroj: | European Journal of Cancer. 49:416-430 |
| ISSN: | 0959-8049 |
| Popis: | Aim To evaluate the evidence for denosumab for the treatment of bone metastases secondary to solid tumours and, using a network meta-analysis, indirectly compare denosumab with bisphosphonates and best supportive care. Data sources MEDLINE (1948 to April 2011), EMBASE (1980 to March 2011), Cochrane Library (all sections) (issue 1, 2011) and Web of Science with Conference Proceedings (1970 to May 2011) and additional meeting abstracts (2010 and 2011) were searched. Study eligibility, participants and interventions Only randomised controlled trials assessing denosumab, bisphosphonates or best supportive care in patients with bone metastases from any solid tumour were included. Synthesis Direct evidence comparing denosumab and zoledronic acid was assessed for breast cancer, prostate cancer and other solid tumours. Denosumab was compared with pamidronate and best supportive care through a network meta-analysis for each tumour type. The primary outcomes were time to first skeletal related event (SRE) and time to first and subsequent SRE. Secondary outcomes were skeletal morbidity rate, pain, quality of life (QoL) and overall survival. Results Denosumab was found to be more effective in delaying the time to first SRE and reducing the risk of first and subsequent SRE compared to zoledronic acid, placebo and pamidronate. In breast and prostate cancer, denosumab was effective in reducing skeletal morbidity rate compared with placebo. The lack of published data on pain and QoL meant that firm conclusions could not be made. Denosumab did not appear to have an affect on overall survival. Limitations Network meta-analyses are subject to uncertainties and potential biases. Conclusions Denosumab is effective in preventing SRE, but the effect on pain and QoL is unclear. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect